反応式
[NH2:1][C:2]1[C:3]2[C:10]([C:11]([C:13]3[CH:14]=[C:15]([NH:19][C:20]([NH:22][C:23]4[CH:28]=[C:27]([Cl:29])[CH:26]=[C:25]([Cl:30])[CH:24]=4)=[O:21])[CH:16]=[CH:17][CH:18]=3)=[O:12])=[CH:9][N:8]([CH:31]3[CH2:36][CH2:35][NH:34][CH2:33][CH2:32]3)[C:4]=2[N:5]=[CH:6][N:7]=1.CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F.[C:61](O)(=[O:68])[C:62]1[CH:67]=[CH:66][CH:65]=[CH:64][CH:63]=1>CN(C=O)C>[NH2:1][C:2]1[C:3]2[C:10]([C:11]([C:13]3[CH:14]=[C:15]([NH:19][C:20]([NH:22][C:23]4[CH:28]=[C:27]([Cl:29])[CH:26]=[C:25]([Cl:30])[CH:24]=4)=[O:21])[CH:16]=[CH:17][CH:18]=3)=[O:12])=[CH:9][N:8]([CH:31]3[CH2:32][CH2:33][N:34]([C:61](=[O:68])[C:62]4[CH:67]=[CH:66][CH:65]=[CH:64][CH:63]=4)[CH2:35][CH2:36]3)[C:4]=2[N:5]=[CH:6][N:7]=1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
A solution of 1-[3-(4-Amino-7-piperidin-4-yl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-3-(3,5-dichloro-phenyl)-urea (100 mg, 0.19 mmol), HATU (73 mg, 0.19 mmol), and benzoic acid (24 mg, 0.19 mmol) in DMF (5 mL) was stirred for 12 hours at room temperature The reaction mixture concentrated in vacuo. Purification by reverse phase preparative HPLC (HPLC method 2) provided the title compound as a white solid (17 mg, 14%). MS: 629.5 (MH+); HPLC Rf: 2.5 min. (HPLC method 2); HPLC purity: 100%.
後処理
- concentrationconcentrated in vacuo
- customPurification by reverse phase preparative HPLC (HPLC method 2)
出典と根拠
- ORDレコード
- ord-a3cc42bdbe0a45d39f5fd35d0e9921de
- 出典データセット
- uspto-grants-2007_09
- 特許番号
- US07271262B2
関連ノート
読み込み中…